Notable companies
The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Medtronic plc (NYSE:MDT), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Sarepta Therapeutics (NASDAQ:SRPT).
Industry description
The investment seeks to provide long-term growth of capital.
Under normal circumstances, the Tema Neuroscience and Mental Health ETF seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in neuroscience and mental health companies. A company is generally considered to be a neuroscience or mental health company that derives at least 50% of revenues from neuroscience or neurology-related diseases, or mental health. The fund is non-diversified.
Market Cap
The average market capitalization across the Tema Neuroscience and Mental Health ETF ETF is 29.75B. The market cap for tickers in the group ranges from 174.17M to 560.87B. LLY holds the highest valuation in this group at 560.87B. The lowest valued company is VYGR at 174.17M.
High and low price notable news
The average weekly price growth across all stocks in the Tema Neuroscience and Mental Health ETF ETF was 1%. For the same ETF, the average monthly price growth was 5%, and the average quarterly price growth was -6%. RNA experienced the highest price growth at 29%, while VRTX experienced the biggest fall at -21%.
Volume
The average weekly volume growth across all stocks in the Tema Neuroscience and Mental Health ETF ETF was 9%. For the same stocks of the ETF, the average monthly volume growth was 25% and the average quarterly volume growth was 56%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 63
P/E Growth Rating: 77
Price Growth Rating: 61
SMR Rating: 77
Profit Risk Rating: 78
Seasonality Score: -26 (-100 ... +100)